Topic

Articles

David Jimenez, President of Janssen Pulmonary Hypertension, talks about how he is delivering on the company’s mission to support earlier diagnosis of people with pulmonary arterial hypertension (PAH).

Showing Up Every Day for People with PAH: David Jimenez, Janssen Pharmaceuticals

Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mjhlifesciences.com

With a background in pharma and biotech, ImmunoGen president and CEO Mark Enyedy discusses his dedication to oncology and the lessons he’s learned along the way.

Q&A: Mark Enyedy, ImmunoGen

Dr. Randall N. Hyer, SVP Global Medical Affairs at Moderna, talks about the strategies that have helped the company grow from startup to multi-billion-dollar firm in a decade.

Determining the Right Combination of Employees and New Technologies at Moderna

Ester Banque, senior vice president and head of Intercontinental Commercial at Bristol Myers Squibb, talks purpose and perseverance—both in her own career journey and her group’s mission to topple barriers to drug access in diverse and hard-to-reach regions.

A Global Vision for Access

Milan Kalawadia, Senior Vice President, Head of US Commercial Operations at Dr. Reddy‘s, talks about his 15+ years with the India-headquartered company, maintaining a leading position in the generics industry, and the challenges of doing business during the pandemic.

Keeping Cost-Competitive: Milan Kalawadia, Dr. Reddy’s

Insights from AmerisourceBergen EVP and Chief Strategy Officer, Leslie Donato.

How an Innovation Mindset Fuels Revenue Expansion for a Top 10 Fortune 500 Company

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

GSK‘s President of US Pharmaceuticals, Maya Martinez-Davis, outlines her organization’s evolving diversity and inclusion commitments. 

D&I at GSK

Marcelo Bigal, M.D, Ph.D, President and CEO of Ventus Therapeutics, talks about how technological innovation in the field of small molecule drug development has created new opportunities for pursuing undruggable targets, building on the well-established strengths of small molecule medicines.










Broadening the Scope of Small Molecules: Ventus Therapeutics

Influenced by lessons from the playing field, former rugby athlete James Robinson, today president and CEO of Urovant Sciences, discusses the keys to establishing a high-performing team culture in biopharma—and the end-game wins in treatment gain and patient need.

Coach First, CEO Second

Newly appointed General Manager (UK) at Global Blood Therapeutics (GBT), Nigel Nicholls talks about the company’s vision for Europe and the UK and the health inequity faced by the sickle cell disease community.

Executive Profiles